Sylvain Perruche/LinkedIn
Apr 4, 2026, 08:36
Sylvain Perruche: Reactivating the Body Own Resolution Program in Inflammatory Disease
Sylvain Perruche, Founder and CEO of Med’Inn’Pharma, Co-Founder and Member of the Scientific Committee at Innovative Therapies Days, shared a post on LinkedIn:
“Inflammatory diseases have traditionally been treated by blocking the immune system.
Over the past decades, therapies have evolved:
- from broad immunosuppression
- to targeted cytokine inhibition
- to cell therapies
But the next frontier may be different.
Instead of suppressing inflammation, what if we could reactivate the body’s own resolution program?
At Med’Inn’Pharma, we are developing macrophage-derived secretome therapeutics designed to restore immune homeostasis and promote tissue repair.
A shift from blocking inflammation – resolving it.”
Stay updated with Hemostasis Today.
-
Aug 22, 2026, 14:50Marco Meloni: Clinical Management of the Diabetic Foot Attack
-
Aug 22, 2026, 14:41Nico Gagelmann: What is the Future for Patients with Myeloproliferative Neoplasms?
-
Aug 22, 2026, 14:36Arun V J: Leadership Is a Practice, Not a Position – TRAM Masterclass with Judith Chapman
-
Aug 22, 2026, 13:38Jerome Hadjadj: A New Approach to Refractory Immune Thrombocytopenia
-
Aug 22, 2026, 13:25Christopher Robinson: Hematologic Response to Iron Therapy and Stillbirth Risk
-
Aug 22, 2026, 13:24Philippa Hill: Blood Clot Awareness – Recognize the Signs, Prevent the Risk
-
Aug 22, 2026, 13:21Chokri Ben Lamine: ASH 2026 Adult Primary ITP Guidelines – Practice-Changing Update
-
Aug 22, 2026, 13:07Saneha Anjum Shaikh: Blood Bank Basics and Quality Control in Automation
-
Aug 22, 2026, 11:36Bernardo Gindri: How platelets Influence Cancer Progression